Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MAP2K1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP2K1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP2K1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAP2K1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/MAP2K1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005140317 | Oral cavity | LP | stress-activated MAPK cascade | 84/4623 | 239/18723 | 1.79e-04 | 2.00e-03 | 84 |
GO:200063714 | Oral cavity | LP | positive regulation of gene silencing by miRNA | 17/4623 | 30/18723 | 1.81e-04 | 2.01e-03 | 17 |
GO:006096414 | Oral cavity | LP | regulation of gene silencing by miRNA | 24/4623 | 49/18723 | 2.00e-04 | 2.18e-03 | 24 |
GO:006014714 | Oral cavity | LP | regulation of posttranscriptional gene silencing | 25/4623 | 52/18723 | 2.15e-04 | 2.33e-03 | 25 |
GO:006071113 | Oral cavity | LP | labyrinthine layer development | 22/4623 | 44/18723 | 2.51e-04 | 2.63e-03 | 22 |
GO:006014814 | Oral cavity | LP | positive regulation of posttranscriptional gene silencing | 17/4623 | 31/18723 | 3.09e-04 | 3.15e-03 | 17 |
GO:001000111 | Oral cavity | LP | glial cell differentiation | 78/4623 | 225/18723 | 4.82e-04 | 4.52e-03 | 78 |
GO:009892714 | Oral cavity | LP | vesicle-mediated transport between endosomal compartments | 21/4623 | 43/18723 | 5.18e-04 | 4.82e-03 | 21 |
GO:007030216 | Oral cavity | LP | regulation of stress-activated protein kinase signaling cascade | 68/4623 | 195/18723 | 8.92e-04 | 7.64e-03 | 68 |
GO:003021613 | Oral cavity | LP | keratinocyte differentiation | 51/4623 | 139/18723 | 1.05e-03 | 8.84e-03 | 51 |
GO:000189217 | Oral cavity | LP | embryonic placenta development | 33/4623 | 82/18723 | 1.34e-03 | 1.07e-02 | 33 |
GO:004502213 | Oral cavity | LP | early endosome to late endosome transport | 19/4623 | 40/18723 | 1.44e-03 | 1.14e-02 | 19 |
GO:000991315 | Oral cavity | LP | epidermal cell differentiation | 69/4623 | 202/18723 | 1.53e-03 | 1.19e-02 | 69 |
GO:003287216 | Oral cavity | LP | regulation of stress-activated MAPK cascade | 66/4623 | 192/18723 | 1.60e-03 | 1.23e-02 | 66 |
GO:006042513 | Oral cavity | LP | lung morphogenesis | 22/4623 | 50/18723 | 2.18e-03 | 1.58e-02 | 22 |
GO:00609685 | Oral cavity | LP | regulation of gene silencing | 32/4623 | 81/18723 | 2.24e-03 | 1.62e-02 | 32 |
GO:19037981 | Oral cavity | LP | regulation of production of miRNAs involved in gene silencing by miRNA | 13/4623 | 25/18723 | 2.98e-03 | 2.04e-02 | 13 |
GO:004830811 | Oral cavity | LP | organelle inheritance | 9/4623 | 15/18723 | 3.82e-03 | 2.48e-02 | 9 |
GO:004831311 | Oral cavity | LP | Golgi inheritance | 9/4623 | 15/18723 | 3.82e-03 | 2.48e-02 | 9 |
GO:003134615 | Oral cavity | LP | positive regulation of cell projection organization | 109/4623 | 353/18723 | 4.59e-03 | 2.93e-02 | 109 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0421810 | Cervix | CC | Cellular senescence | 49/1267 | 156/8465 | 1.30e-07 | 1.63e-06 | 9.61e-07 | 49 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0466612 | Cervix | CC | Fc gamma R-mediated phagocytosis | 31/1267 | 97/8465 | 1.78e-05 | 1.42e-04 | 8.40e-05 | 31 |
hsa0517016 | Cervix | CC | Human immunodeficiency virus 1 infection | 55/1267 | 212/8465 | 1.80e-05 | 1.42e-04 | 8.40e-05 | 55 |
hsa0401210 | Cervix | CC | ErbB signaling pathway | 28/1267 | 85/8465 | 2.40e-05 | 1.82e-04 | 1.08e-04 | 28 |
hsa0513516 | Cervix | CC | Yersinia infection | 39/1267 | 137/8465 | 3.27e-05 | 2.41e-04 | 1.42e-04 | 39 |
hsa0407110 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa0521010 | Cervix | CC | Colorectal cancer | 27/1267 | 86/8465 | 8.60e-05 | 5.57e-04 | 3.30e-04 | 27 |
hsa052197 | Cervix | CC | Bladder cancer | 16/1267 | 41/8465 | 1.45e-04 | 9.05e-04 | 5.35e-04 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP2K1 | SNV | Missense_Mutation | novel | c.12G>T | p.Lys4Asn | p.K4N | Q02750 | protein_coding | deleterious(0.01) | benign(0.135) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP2K1 | SNV | Missense_Mutation | | c.256N>G | p.Ser86Ala | p.S86A | Q02750 | protein_coding | tolerated(0.67) | benign(0.027) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
MAP2K1 | SNV | Missense_Mutation | | c.607N>A | p.Glu203Lys | p.E203K | Q02750 | protein_coding | deleterious(0) | possibly_damaging(0.838) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MAP2K1 | SNV | Missense_Mutation | rs754765552 | c.1006G>C | p.Asp336His | p.D336H | Q02750 | protein_coding | deleterious(0.03) | possibly_damaging(0.897) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MAP2K1 | insertion | Frame_Shift_Ins | novel | c.845_846insCCCAGGCTGGAGTGCAGTGGTGCGATCT | p.Ala283ProfsTer12 | p.A283Pfs*12 | Q02750 | protein_coding | | | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAP2K1 | SNV | Missense_Mutation | novel | c.770N>T | p.Ala257Val | p.A257V | Q02750 | protein_coding | tolerated(0.11) | benign(0.274) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP2K1 | SNV | Missense_Mutation | | c.1046N>A | p.Arg349Lys | p.R349K | Q02750 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP2K1 | SNV | Missense_Mutation | | c.1099N>C | p.Glu367Gln | p.E367Q | Q02750 | protein_coding | tolerated(0.07) | benign(0.062) | TCGA-VS-A94Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP2K1 | SNV | Missense_Mutation | | c.308N>A | p.Ile103Asn | p.I103N | Q02750 | protein_coding | deleterious(0) | possibly_damaging(0.866) | TCGA-VS-A9UQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
MAP2K1 | SNV | Missense_Mutation | | c.692N>T | p.Ser231Leu | p.S231L | Q02750 | protein_coding | deleterious(0) | possibly_damaging(0.871) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | SELUMETINIB | SELUMETINIB | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | WX-554 | WX-554 | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | Pyridic ketone derivative 1 | | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | PANITUMUMAB | PANITUMUMAB | 31227518 |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | allosteric modulator | 363894205 | TAK-733 | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | allosteric modulator | 249565604 | BINIMETINIB | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | BAY 869766 | | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | inhibitor | PIMASERTIB | PIMASERTIB | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | inhibitor | CHEMBL2146883 | COBIMETINIB | |
5604 | MAP2K1 | ENZYME, DRUGGABLE GENOME, KINASE, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, DRUG RESISTANCE, TYROSINE KINASE, NUCLEAR HORMONE RECEPTOR | | VEMURAFENIB | VEMURAFENIB | 22197931,7651428,18632602,19915144,23569304,25157968 |